Kinase Inhibitor Trials Show Melanoma Benefits | News | Drug Discovery and Development Magazine
― Findings from GlaxoSmithKline (GSK) plc’s Phase 3 clinical study program evaluating single agent therapy with the targeted anti-cancer agents, dabrafenib (below left structure) and trametinib (below right structure), in patients with BRAF V600 mutation positive metastatic melanoma have been released. Both the BREAK3 study of dabrafenib (BRAF inhibitor) and the METRIC study of trametinib (MEK inhibitor) demonstrated a statistically significant benefit in the length of time patients with [...].
